Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.65 |
| ▸ | MC4R | P32245 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10416634 | 0.89 | SIGMAR1 (0.55) | KMT2AMEN1SIGMAR1MC4RLMNA | |
| SCHEMBL2395111 | 0.85 | RECQL (0.62) | KMT2AMEN1SIGMAR1DRD4ACHE | |
| SCHEMBL25537483 | 0.84 | KMT2A (0.73) | KMT2AMEN1LMNACYP1A2CYP2C19 | |
| SCHEMBL2479586 | 0.81 | KMT2A (0.69) | KMT2AMEN1SIGMAR1LMNACYP1A2 | |
| SCHEMBL2029947 | 0.81 | KMT2A (0.69) | KMT2AMEN1LMNACYP1A2CYP2C19 | |
| SCHEMBL10196835 | 0.81 | KMT2A (1.00) | KMT2AMEN1LMNALTA4HPOLB | |
| SCHEMBL2064262 | 0.81 | KMT2A (0.64) | KMT2AMEN1SIGMAR1MC4RLMNA | |
| SCHEMBL10256869 | 0.81 | SLC6A3 (0.63) | KMT2AMEN1SIGMAR1CYP1A2ACHE | |
| SCHEMBL13982034 | 0.81 | KMT2A (0.74) | KMT2AMEN1LMNACYP1A2CYP2C19 | |
| SCHEMBL1427500 | 0.81 | KMT2A (0.69) | KMT2AMEN1LMNACYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113087684-B | Application of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2022-06-21 | — | — | CN | claimed |
| CN-113087684-A | Application of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2021-07-09 | — | — | CN | claimed |
| CN-114583263-B | Electrolyte, positive electrode, lithium ion battery and vehicle | 比亚迪股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-113201020-B | Preparation method of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2022-10-04 | — | — | CN | disclosed |
| CN-113087684-B | Application of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2022-06-21 | — | — | CN | disclosed |
| CN-114583263-A | Electrolyte, positive electrode, lithium ion battery and vehicle | 比亚迪股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-03-22 | — | — | US | disclosed |
| CN-113201020-A | Preparation method of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2021-08-03 | — | — | CN | disclosed |
| CN-113087684-A | Application of bis (triphenylphosphine) carbonyl ruthenium dichloride monohydrate | 浙江工业大学 | 2021-07-09 | — | — | CN | disclosed |
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-8828641-B2 | Chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION GLAXOSMITHKLINE | 2005-09-01 | — | — | US | disclosed |
| US-20050059662-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2005-03-17 | — | — | US | disclosed |
| US-6670366-B1 | Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors; impotence; pyrazolo(4,3-d)pyrimidin-7-ones | PFIZER INC | 2003-12-30 | — | — | US | disclosed |
| EP-0995750-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. (US) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059662-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | KMT2A 4434/4885MEN1 549/4885SIGMAR1 1329/4885 |
| US-20070037808-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | KMT2A 3389/4885MEN1 4811/4885SIGMAR1 1319/4885 |
| US-20050192297-A1 | Quinazolinone compounds with reduced bioaccumulation | MC4R, MC2R, MC3R | KMT2A 3925/4885MEN1 585/4885SIGMAR1 348/4885 |
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | JAK1, JAK2, JAK3 | KMT2A 383/4885MEN1 2505/4885SIGMAR1 1288/4885 |
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | JAK1, JAK2, JAK3 | KMT2A 383/4885MEN1 2505/4885SIGMAR1 1288/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | KMT2A 486/4885MEN1 3722/4885SIGMAR1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.